SHAHEAN FAYAZ: Open Payments
NPI 1255788170 · LUMBERTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 19 payments from 10 companies in 2025. Trend: 2023 $954 · 2024 $769 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $170 |
| Gilead Sciences, Inc. | 1 | $92 |
| MIMEDX Group, Inc. | 1 | $91 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $91 |
| Novo Nordisk Inc | 4 | $72 |
| Axsome Therapeutics, Inc. | 1 | $69 |
| ABBVIE INC. | 2 | $44 |
| GENZYME CORPORATION | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
Products named: Livdelzi, Kerendia, AIRSUPRA, BREZTRI, Auvelity, DUPIXENT, Rybelsus, Ozempic.
Industry payments across TX — which companies pay providers there.
